Related Experiment Video

Updated: Oct 13, 2026

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease
06:25

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease

Published on: March 29, 2024

Tamoxifen-induced cell death in malignant melanoma cells: possible involvement of the insulin-like growth factor-1

L Kanter-Lewensohn1, L Girnita, A Girnita

  • 1Cellular and Molecular Tumor Pathology, CCK R8:04, Department of Oncology/Pathology, Karolinska Hospital, 171 76, Stockholm, Sweden.

Molecular and Cellular Endocrinology
|August 15, 2000
PubMed

Insights

Tamoxifen (TAM) induces melanoma cell death by interfering with the insulin-like growth factor-1 receptor (IGF-1R). This suggests TAM

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Tamoxifen (TAM), an estrogen receptor (ER) blocker, shows potential in inducing malignant melanoma cell death.
  • Melanoma cells typically lack classical ER expression, suggesting alternative mechanisms for TAM's cytotoxic effects.
  • The insulin-like growth factor-1 receptor (IGF-1R) is crucial for melanoma cell survival.

Purpose of the Study:

  • To investigate if TAM's cytotoxic effect on melanoma cells involves interference with the IGF-1R.
  • To explore the mechanism by which TAM affects IGF-1R function and expression in melanoma.

Main Methods:

  • Treatment of multiple melanoma cell lines with TAM (≥15 microm).
  • Assessment of cell death, IGF-1 binding to IGF-1R, IGF binding protein (IGFBP) release, and IGF-1R beta-subunit tyrosine phosphorylation.

Main Results:

  • TAM induced melanoma cell death within 48 hours.
  • TAM treatment showed moderate inhibition of IGF-1 binding to IGF-1R.
  • TAM did not significantly alter IGFBP release but effectively blocked IGF-1R beta-subunit tyrosine phosphorylation.

Conclusions:

  • TAM-induced cytotoxicity in malignant melanoma may result from the inactivation of the IGF-1R.
  • The mechanism involves blocking IGF-1R signaling rather than altering IGF-1 binding or IGFBP levels.

More Related Videos

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...